Mei-Wei Lin
Wednesday 3rd July 2024, 09:00-10:00
Current advances and future prospects of cell therapy for cancer treatment
Mei-Wei was awarded an institute sponsorship of Industrial Technology Research Institute (ITRI) for PhD study. She obtained PhD at National Tsing Hua University where she specialized in synthetic biology and CRISPR technology. She engineered baculovirus with a miRNA senor-based switch to selectively turn on killing module in cancer cell, and altered the transcriptome of CHO cell to increase the yield and activity of antibody using CRISPR/Cas13d. She has worked in ITRI more than 15 years. She focused on cell therapy, antibody production, and gene editing to conquer the problems in cancer treatment. She established two patient-derived cancer stem cells clinically relevant for drug evaluation. She is also a key member in developing an anti-immune checkpoint antibody for cancer therapy. This study earned National Innovation Award in 2022 and were issued patents of Taiwan, Japan and US. She also initiated the cooperation with System Biosciences (SBI) in USA for gene editing. .
Visit us on Social Media
#ECB2024
Please note: All information requested on the website and registration process is strictly for the use of the Congress in compliance with international privacy legislation. By completing this registration form you will agree that the Congress will use this data to keep you fully informed of the Congress in 2024. The data will then be retained by the Congress secretariat for the purposes of informing you about activities and future meetings. On the registration form, You will also have the opportunity to agree separately to allow key data (Name, Company, Email Address) to be shared with sponsors and exhibitors who are participating in the Congress in 2024. We will not pass any details to any companies not participating in the Congress in 2024.